Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to OSU, Alnylam, Medtronic, and More

Premium

Title: Method for Diagnosing Acute Lymphomic Leukemia using miR-222

Patent Number: 8,349,560

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The invention comprises “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins,” the patent's abstract states.


Title: Method for Diagnosing Acute Lymphomic Leukemia using miR-125b

Patent Number: 8,349,561

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The invention comprises “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins,” the patent's abstract states.


Title: Method for Diagnosing Poor Survival Prognosis Colon Cancer using Let-7g

Patent Number: 8,349,568

Filed: Nov. 14, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention comprises “novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Single-Stranded Extended Dicer-Substrate Agents and Methods for the Specific Inhibition of Gene Expression

Patent Number: 8,349,809

Filed: June 25, 2010

Inventor: Bob Brown, Dicerna Pharmaceuticals

“The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double-stranded nucleic acid in an amount effective to reduce expression of a target gene in a cell,” the patent's abstract states. “The dsNAs of the invention possess a single-stranded extension (in most embodiments, the single-stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single-stranded extended Dicer-substrate siRNAs were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.”


Title: Conserved HBV and HCV Sequences Useful for Gene Silencing

Patent Number: 8,350,021

Filed: June 10, 2004

Lead Inventor: Catherine Pachuk, Alnylam Pharmaceuticals (Nucleonics)

The patent, its abstract states, claims “conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.”


Title: RNAi Modulation of RSV and Therapeutic Uses Thereof

Application Number: 20130005791

Filed: March 29, 2012

Lead Inventor: Rachel Meyers, Alnylam Pharmaceuticals

The invention, the patent's abstract states, is “based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject. These findings can be applied to other respiratory viruses.”


Title: Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus

Application Number: 20130005793

Filed: June 28, 2012

Lead Inventor: Daniel Chin, Arrowhead Research

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a hepatitis B virus gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by hepatitis B virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a hepatitis B virus gene in a cell.”


Title: Methods and Sequences to Suppress Primate Huntington Gene Expression

Application Number: 20130005794

Filed: Aug. 31, 2012

Lead Inventor: William Kaemmerer, Medtronic

The invention, the patent application's abstract states, comprises “sequences, molecules, and methods used to suppress the expression of [Huntington's disease] genes encoding for huntingtin protein in primates including Macaca mulatto and Homo sapiens. These sequences, molecules, and methods aid in the study of the pathogenesis of [Huntington's disease] and can also provide a treatment for this disease.”


Title: Method for Proliferating Cardiomyocytes using microRNA

Application Number: 20130005796

Filed: March 11, 2011

Lead Inventor: Kayoko Kawashimi, Daiichi Sankyo

The patent, its abstract states, claims “a method for proliferating cardiomyocytes … [using an] miRNA that promotes the proliferation of cardiomyocytes ... a vector for the treatment of heart diseases; and a pharmaceutical composition or the like for the treatment of heart diseases. … The miRNA is preferably one selected from the group consisting of miR-148a, miR-148b, miR-152 and miR-373 that are mature miRNAs, precursors of the aforementioned miRNAs, and mutants and analogues of the miRNAs and the precursors.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.